Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
Rhea-AI Summary
Silexion Therapeutics (NASDAQ: SLXN) priced a public offering of 3,846,161 ordinary shares (or equivalents) and accompanying Series E warrants to purchase up to 3,846,161 ordinary shares at a combined public offering price of $0.65 per share and warrant.
The Series E warrants have a $0.65 exercise price, are immediately exercisable, and expire five years from issuance. Gross proceeds are expected to be approximately $2.5 million, before fees and expenses, with closing anticipated on or about August 13, 2026. According to Silexion Therapeutics, net proceeds will fund advancement of its SIL204 Phase 2/3 clinical trial and general corporate purposes. H.C. Wainwright & Co. is acting as exclusive placement agent under an effective Form S‑1 registration statement.
Positive
- $2.5 million expected gross proceeds to strengthen cash resources
- Financing earmarked to advance SIL204 Phase 2/3 clinical trial
- Series E warrants immediately exercisable for up to 3,846,161 additional shares
- Offering conducted under effective Form S-1 registration, reducing execution risk
Negative
- Issuance of 3,846,161 new shares (or equivalents) creates shareholder dilution
- Additional dilution possible if 3,846,161 Series E warrants are fully exercised
News Explained
The $2.5 million gross offering equals 61.7 days of first-quarter operating cash use, but cash is not in hand until the expected August 13 closing.
Silexion Therapeutics has priced, but not yet closed, an offering of
The effective Form S-1 is the registration vehicle, but registration alone sells nothing, so the disclosed cash and ownership effects remain conditional on the expected closing.
Using first-quarter 2026 operating cash outflow as the basis, the expected
Sources and calculations
- Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering (2026-08-11)
- Dilution (2026-07-17)
- Form S-1 purpose (2026-07-17)
- Silexion Therapeutics 2026 first-quarter fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $2,500,000 / ($3,646,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $2,413,000 / ($3,646,000 / 90) = [object Object]
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Warrant exercise | Negative | -42.1% | Immediate warrant exercise generated proceeds while adding new Series C and Series D warrants. |
| Sep 11 | Public offering | Negative | +9.9% | The $6.0 million offering included shares and accompanying Series A and Series B warrants. |
| Jul 31 | Warrant exercise | Negative | -37.9% | Warrant exercises generated $1.8 million while new warrants were issued. |
| Jan 29 | Warrant exercise | Negative | -34.7% | The company announced $3.3 million of proceeds and additional warrants. |
| Jan 15 | Public offering | Negative | -39.7% | The $5.0 million offering included ordinary shares and immediately exercisable warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-tagged events were negative on average, with four of five historical reactions aligned with the announcement sentiment.
Key Terms
rna interference medical
small interfering rna medical
warrants financial
form s-1 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,846,161 of the Company’s ordinary shares (or ordinary share equivalents) and series E warrants to purchase up to 3,846,161 ordinary at a combined public offering price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-298137), which was declared effective by the Securities and Exchange Commission (the “SEC”) on August 11, 2026. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), has initiated a Phase 2/3 clinical trial at Tel Aviv Sourasky Medical Center. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information, please visit: https://silexion.com
Notice Regarding Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, and the intended use of net proceeds from the offering, are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, or “potential”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the inherent uncertainties associated with preclinical research and drug development, including the risk that preclinical findings may not translate to clinical outcomes; (ii) Silexion’s ability to successfully complete additional preclinical studies and initiate and conduct clinical trials, including the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer; (iii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iv) the impact of the regulatory environment and compliance complexities, including site-level approvals, conditions and clearances required prior to study commencement at each clinical site in Israel and Germany, and the timing and outcome of additional regulatory submissions and reviews in further EU member states, the United States, and other jurisdictions; (v) expectations regarding future partnerships or other relationships with third parties; (vi) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vii) Silexion’s ability to maintain its Nasdaq listing; and (viii) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 15, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com
